NEW YORK, Sept. 11, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Xoma Corporation XOMA securities between November 6, 2014 and July 21, 2015.
Click here to learn about the case: http://docs.wongesq.com/XOMA-Info-Request-Form-863. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements that Xoma Corporation's EYEGUARD-B clinical trial would succeed and/or surpass expectations across the study's primary endpoint. On July 22, 2015, defendants revealed that the Phase 3 EYEGUARD-B study had failed. On this news, the price of Xoma stock declined by $3.48 per share, or over 79%, on extremely heavy trading volume.
If you suffered a loss in Xoma you have until September 22, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/XOMA-Info-Request-Form-863.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.